Abcam

Amgen is a global leader in biotechnology, dedicated to the development of innovative biologic medicines that address serious illnesses, particularly in areas with limited treatment options. The company's mission encompasses a commitment to scientific advancement, patient safety, and corporate responsibility, reflecting its core values of integrity and excellence. With a strong focus on research and development, Amgen employs cutting-edge technologies, including AI and data science, to optimize clinical trials and enhance drug design. The company also prioritizes community investment, diversity, and sustainability, striving to make a positive impact on healthcare access and health equity worldwide. Generated from the website

Cogo Labs, located in the Kendall Square Innovation District of Cambridge, MA, has established itself as a leading incubator for startups over the past decade. Recognized as Boston's #1 in the 50 Best Small Companies to Work for, it serves as a hub for innovation and entrepreneurship. The company offers a unique "Incubation as a Service" model, allowing startups to accelerate their growth by utilizing Cogo's comprehensive technology and operations platform. Through collaboration and shared insights, Cogo helps its companies leverage collective knowledge to navigate their entrepreneurial journeys. Generated from the website

Cequent Pharmaceuticals, a privately held biopharmaceutical company based in Cambridge, Massachusetts, is at the forefront of developing novel therapeutics aimed at preventing and treating a variety of human diseases, including inflammatory diseases and cancer. Established in 2006, the company leverages its proprietary TransKingdom RNA interference (tkRNAi) technology to target specific disease-causing genes safely and effectively using non-pathogenic bacteria as delivery vehicles. The tkRNAi platform enables the development of drug candidates that can silence one or more cellular genes simultaneously, offering a powerful alternative to traditional small molecules and monoclonal antibodies. With its foundation rooted in groundbreaking scientific research from the Institut Pasteur in Paris and Beth Israel Deaconess Medical Center at Harvard Medical School, Cequent is poised to make significant advancements in the biopharmaceutical landscape. Generated from the website